151 related articles for article (PubMed ID: 34493151)
21. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E; Gerds AT; Hobbs GS; Winton EF; Goel S; Wadleigh M; Tremblay D; Moshier E; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):697-703.e1. PubMed ID: 32624445
[TBL] [Abstract][Full Text] [Related]
22. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
Naqvi K; Daver N; Pemmaraju N; Bose P; Garcia-Manero G; Cortes J; Kantarjian HM; Verstovsek S
Leuk Lymphoma; 2017 Apr; 58(4):866-871. PubMed ID: 27494751
[TBL] [Abstract][Full Text] [Related]
23. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
24. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
[TBL] [Abstract][Full Text] [Related]
25. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
Mwirigi A; Galli S; Keohane C; Raj K; Radia DH; Harrison CN; McLornan DP
Br J Haematol; 2014 Dec; 167(5):714-6. PubMed ID: 25048366
[No Abstract] [Full Text] [Related]
27. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Eghtedar A; Verstovsek S; Estrov Z; Burger J; Cortes J; Bivins C; Faderl S; Ferrajoli A; Borthakur G; George S; Scherle PA; Newton RC; Kantarjian HM; Ravandi F
Blood; 2012 May; 119(20):4614-8. PubMed ID: 22422826
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
Harrison CN; Talpaz M; Mead AJ
Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
[TBL] [Abstract][Full Text] [Related]
29. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
[TBL] [Abstract][Full Text] [Related]
30. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.
Cortés AA; Diaz RA; Hernández-Campo P; Gorrochategui J; Primo D; Robles A; Morales ML; Ballesteros J; Rapado I; Gallardo M; Linares M; Martínez-López J
Haematologica; 2019 May; 104(5):937-946. PubMed ID: 30545926
[TBL] [Abstract][Full Text] [Related]
31. ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.
Buks R; Brusson M; Cochet S; Galochkina T; Cassinat B; Nemazanyy I; Peyrard T; Kiladjian JJ; de Brevern AG; Azouzi S; El Nemer W
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805426
[TBL] [Abstract][Full Text] [Related]
32. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
[TBL] [Abstract][Full Text] [Related]
33. Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.
Zhao Y; Chen P; Dou L; Li F; Li M; Xu L; Chen J; Jia M; Huang S; Wang N; Luan S; Yang J; Bai N; Liu D
Drug Des Devel Ther; 2022; 16():817-825. PubMed ID: 35370398
[TBL] [Abstract][Full Text] [Related]
34. Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib.
Rumi E; Sant'Antonio E; Cavalloni C; Comolli G; Ferretti VV; Cassaniti I; Pietra D; Trotti C; Ciboddo M; Furione M; Vanni D; Casetti IC; Favaron C; Baldanti F; Arcaini L; Cazzola M
Hematol Oncol; 2020 Oct; 38(4):554-559. PubMed ID: 32583904
[TBL] [Abstract][Full Text] [Related]
35. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
37. [Ruxolitinib prescription in myelofibrosis].
Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
[TBL] [Abstract][Full Text] [Related]
38. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
